The last meaningful regulatory gate just opened. On October 13, the European Commission granted conditional approval for Kimberly-Clark to acquire Kenvue, contingent on Kimberly-Clark divesting its tampon and other feminine hygiene brands across the European Economic Area. The buyer for the divestiture package has not been publicly identified by the European Commission. With that, the path to closing a deal nearly a year in the making is clear. The harder question is what exactly Kimberly-Clark has bought.
Kimberly-Clark has cleared the EU’s merger review for its $48.7 billion acquisition of Kenvue, but only after agreeing to sell its tampon and other feminine hygiene business in the European Economic Area. The Commission described the divestiture as covering all of Kimberly-Clark’s brands of tampons and other feminine hygiene products in the EEA, including Kotex, along with associated intellectual property, know-how, and staff. Kimberly-Clark is surrendering meaningful shelf space in European drugstores to get what it really wants: the Kenvue portfolio sitting on the other side of the ledger.
What Kimberly-Clark Is Actually Buying
Kenvue is the world’s largest pure-play consumer health company by revenue, with $15.1 billion in net sales in fiscal year 2025. Its portfolio of iconic brands includes Aveeno, BAND-AID, Johnson’s, Listerine, Neutrogena, Nicorette, Tylenol, and Zyrtec. That lineup is exactly what Kimberly-Clark’s Huggies-and-Kleenex revenue base lacks: brands in the medicine cabinet rather than under the kitchen sink.
The combined entity is projected to generate $32 billion in annual revenue and $7 billion in adjusted EBITDA. Kimberly-Clark expects $2.1 billion in annual run-rate synergies. At 14.3 times Kenvue’s trailing adjusted EBITDA, the price is steep. Stripped of synergies, it is a premium valuation for a business that has been delivering modest growth. Kenvue’s second-quarter 2026 net sales grew 3.0%, with organic sales up 1.6%.
The Litigation Kimberly-Clark Inherits
Tylenol is the crown jewel of the acquisition. It is also the most complicated asset in the portfolio. In July 2026, the U.S. Court of Appeals for the Second Circuit revived more than 500 lawsuits alleging that acetaminophen use during pregnancy contributed to autism or ADHD in children, after a trial court had excluded plaintiffs’ experts and entered judgment for the defendants. In September 2026, Kenvue and a group of retailer defendants asked the full Second Circuit to rehear the decision. The science behind those claims is contested, and the broader scientific question of whether acetaminophen use during pregnancy causes autism or ADHD remains unresolved.
The legal exposure runs in multiple directions. The federal litigation has remained active at the appellate level, and product liability lawsuits continue to be filed. On top of that, in October 2025, Texas Attorney General Ken Paxton sued Johnson & Johnson and Kenvue, alleging they deceptively marketed Tylenol to pregnant mothers despite what the state claims the companies knew about acetaminophen and neurodevelopmental risk. Kenvue disputes the allegations and maintains that Tylenol is safe when used as directed. Kimberly-Clark will now be the one defending that position.
The Risks Investors Should Weigh
The divestiture requirement is a concrete cost. Kotex is not a footnote; it is Kimberly-Clark’s flagship feminine care brand in a region where the company previously competed. Handing those assets to satisfy Brussels narrows the combined company’s European consumer footprint before the deal even closes.
The Tylenol litigation is a longer-tailed risk. Dollar amounts are unquantified, the appellate process is still running, and the Texas attorney general action adds state-level exposure on top of the federal proceedings. Kimberly-Clark is absorbing that uncertainty at a moment when it is also taking on significant debt to fund the cash portion of the transaction.
What Investors Should Watch Next
The closing date is the first milestone. The companies have said the transaction is expected to close in the second half of 2026, subject to regulatory approvals and other customary closing conditions, and Kimberly-Clark has also described the mergers as expected to close in the fourth quarter of 2026. With Brussels satisfied, those remaining conditions are fewer. Once the deal closes, watch the synergy timeline: management committed to adjusted EPS accretion by year two, and the margin structure will be the first test of whether that promise holds.
On the litigation front, the Second Circuit’s next steps on the Tylenol expert-testimony dispute will set the terms for what any eventual settlement exposure might look like. A ruling that forecloses the revived 500-plus cases would remove a significant cloud. Anything less keeps the uncertainty alive and priced into the combined stock.
Kimberly-Clark gave up its European tampon business to buy a consumer health empire. Whether the trade was worth it depends entirely on whether Tylenol’s brand value exceeds its legal baggage, and whether $2.1 billion in promised synergies actually materializes on schedule.
